Apellis Pharmaceuticals (NASDAQ:APLS) Receives “Buy” Rating from HC Wainwright

Apellis Pharmaceuticals (NASDAQ:APLS)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a note issued to investors on Friday, Benzinga reports. They presently have a $92.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 82.21% from the stock’s current price.

Other analysts have also issued reports about the company. The Goldman Sachs Group lifted their target price on Apellis Pharmaceuticals from $65.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, January 9th. UBS Group boosted their price objective on Apellis Pharmaceuticals from $87.00 to $89.00 and gave the company a “buy” rating in a report on Monday, March 4th. Needham & Company LLC restated a “buy” rating and issued a $85.00 target price on shares of Apellis Pharmaceuticals in a research note on Thursday. Oppenheimer boosted their target price on Apellis Pharmaceuticals from $75.00 to $79.00 and gave the stock an “outperform” rating in a report on Tuesday, January 30th. Finally, Raymond James boosted their target price on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the stock a “strong-buy” rating in a report on Thursday, January 11th. Three research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $77.93.

Apellis Pharmaceuticals Trading Up 5.3 %

Apellis Pharmaceuticals stock traded up $2.56 during midday trading on Friday, reaching $50.49. The stock had a trading volume of 596,237 shares, compared to its average volume of 1,468,016. Apellis Pharmaceuticals has a twelve month low of $19.83 and a twelve month high of $94.75. The stock has a market capitalization of $6.09 billion, a PE ratio of -11.31 and a beta of 0.88. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10. The stock’s 50-day simple moving average is $58.21 and its 200 day simple moving average is $57.30.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) EPS for the quarter, meeting the consensus estimate of ($0.73). Apellis Pharmaceuticals had a negative return on equity of 178.60% and a negative net margin of 133.34%. The company had revenue of $146.38 million for the quarter, compared to analyst estimates of $143.34 million. During the same period last year, the company posted ($1.50) earnings per share. The firm’s revenue was up 545.9% compared to the same quarter last year. Analysts expect that Apellis Pharmaceuticals will post -1.33 EPS for the current year.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 1,431 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $67.77, for a total transaction of $96,978.87. Following the completion of the sale, the chief financial officer now directly owns 93,338 shares in the company, valued at $6,325,516.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, insider Pascal Deschatelets sold 69,107 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $54.17, for a total value of $3,743,526.19. Following the completion of the transaction, the insider now owns 1,115,983 shares of the company’s stock, valued at $60,452,799.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Timothy Eugene Sullivan sold 1,431 shares of the stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $67.77, for a total transaction of $96,978.87. Following the completion of the transaction, the chief financial officer now directly owns 93,338 shares of the company’s stock, valued at approximately $6,325,516.26. The disclosure for this sale can be found here. Insiders sold 381,011 shares of company stock worth $23,463,657 over the last ninety days. Company insiders own 7.50% of the company’s stock.

Institutional Trading of Apellis Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Wynnefield Capital Inc. bought a new stake in shares of Apellis Pharmaceuticals during the third quarter valued at approximately $380,000. General American Investors Co. Inc. acquired a new stake in shares of Apellis Pharmaceuticals during the third quarter worth $1,712,000. Profund Advisors LLC raised its holdings in shares of Apellis Pharmaceuticals by 114.5% during the third quarter. Profund Advisors LLC now owns 35,153 shares of the company’s stock worth $1,337,000 after acquiring an additional 18,766 shares during the period. Charles Schwab Investment Management Inc. increased its stake in Apellis Pharmaceuticals by 6.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 879,357 shares of the company’s stock valued at $33,451,000 after buying an additional 50,835 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in Apellis Pharmaceuticals by 109.6% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,145,004 shares of the company’s stock valued at $128,400,000 after buying an additional 1,121,497 shares during the last quarter. 96.29% of the stock is owned by institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).